A study to evaulate the effects of antihypercholesterolemic agent, rosuvastain/ezetimibe on immune T-cell in type 2 diabetic patients with hypercholesterolemia

Effects of rosuvastatin/ezetimibe on senescence of CD8+ T-cell in type 2 diabetic patients with hypercholesterolemia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CRIS

Registry ID

KCT0003477

Enrollment

108

Registered

2019-02-08

Start date

2019-05-21

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : rosuvastatin 5mg or ezetimibe/rosuvastatin 10/5 mg once a day per oral administration for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients with type 2 diabetes mellitus 2. serum LDC-C level is 100 mg/dL or more

Exclusion criteria

Exclusion criteria: 1. currently lipid lowering therapy 2. AST/ALT level - more 2.5X than normal 3. CK level - more 3X than normal 4. allergy or side effect to study drug or statin

Design outcomes

Primary

Measure	Time frame
expression rate of senescence CD8+ T-cell	—

Secondary

Measure	Time frame
serum level of LDL-cholesterol	—

Countries

Korea, Republic of

Contacts

Public ContactBon Jeong Ku

Chungnam National University Hospital

bonjeong@cnuh.co.kr+82-42-280-6031

Outcome results